Effect of HIgh-Flow Therapy in Long-Term Oxygen Therapy (HILOT): study protocol for a multicentre, registry-based, randomised clinical trial.
Josefin Sundh, Mirjam Ljunggren, Andreas Palm...
https://pubmed.ncbi.nlm.nih.gov/41634827/Actively Recruiting
Led by Skane University Hospital · Updated on 2025-05-21
310
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effect of adding high-flow oxygen therapy using the Lumis HFT device to regular low-flow oxygen therapy in people with long-term oxygen therapy LTOT for chronic obstructive pulmonary disease COPD or interstitial lung disease ILD. This registry-based, randomized, controlled clinical trial aims to improve evidence-based treatment for patients with chronic respiratory failure, who face a high risk of adverse events and mortality. Participants will be randomly assigned to either receive added high-flow oxygen therapy during nighttime and at their discretion during the day alongside their usual low-flow oxygen therapy, or to continue with standard care using low-flow oxygen therapy alone. The study will last up to one year and is based on data from the Swedish National Registry for Respiratory Failure Swedevox in collaboration with the Swedish Respiratory Society. During the study, researchers will monitor time to first hospitalization or death from any cause over one year as the primary outcome. Secondary outcomes include hospitalization rates, intensive care admissions, mortality rates, exacerbations, quality of life, health status, breathlessness, sleep quality, physical activity, nasal symptoms, and adverse events at several time points. Participant assessments will include regular follow-ups over the year to gather these data and evaluate the impact of the added therapy.
CONDITIONS
Effect of HIgh-flow Therapy in Long-term Oxygen Therapy
M
Magnus Ekström, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Skane University Hospital
Lead Sponsor
Uppsala University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants use added high-flow oxygen therapy during nighttime and optionally daytime alongside their usual low-flow oxygen therapy, or continue with standard low-flow oxygen therapy as part of the trial.
Regular visits as per clinical routine
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Josefin Sundh, Mirjam Ljunggren, Andreas Palm...
https://pubmed.ncbi.nlm.nih.gov/41634827/Skane University Hospital
Lead Sponsor
Uppsala University Hospital
Collaborating Sponsor